- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06081426
Examinar los mecanismos neurobiológicos que subyacen al efecto terapéutico de la dieta cetogénica en el trastorno bipolar (TB)
Dilucidar los mecanismos neurobiológicos que subyacen al efecto terapéutico de la dieta cetogénica en el trastorno bipolar (TB): un estudio mecanicista multidisciplinario
The investigators aim to examine the effect of the ketogenic diet on brain activity, metabolism, and emotions in adults with Bipolar Disorder (BD).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The investigators hypothesize that a ketogenic diet will enhance levels of the ketone body β-Hydroxybutyrate (beta OHB), resulting in reduced mania/hypomania severity and predisposition to mania/hypomania in individuals with BD. To test this hypothesis in depth, the investigators will use a novel, multidisciplinary mechanistic study using multimodal neuroimaging, peripheral markers of mitochondrial metabolism, and participant-derived induced pluripotent stem cell (iPSC)-derived organoids.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jill Morris-Tillman
- Número de teléfono: 412-383-8206
- Correo electrónico: morristillmanje@upmc.edu
Ubicaciones de estudio
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- Reclutamiento
- University of Pittsburgh Medical Center
-
Contacto:
- Jill Morris-Tillman
- Número de teléfono: 412-383-8206
- Correo electrónico: morristillmanje@upmc.edu
-
Investigador principal:
- Mary L Phillps, MD, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
All participants:
- 18-40 years of age
- Not following a ketogenic diet
BD hypomanic group (n=30):
- Meeting sex proportion: 50% female
- Meeting diagnosis proportion: 50:50% Bipolar I: Bipolar II (BDI:II) (Diagnostic and Statistical Manual of Mental Disorders 5; DSM-5)
- Score greater than 10 on the Young Mania Rating Scale score(YMRS)
- BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)
- Has a primary care provider (if enrolled in ketogenic diet phase)
BD euthymic group (n=30):
- Meeting sex proportion: 50% female
- Meeting diagnosis proportion: 50:50% BDI:II (DSM-5)
- Score less than or equal to 10 on YMRS
- BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)
- Has a primary care provider (if enrolled in ketogenic diet phase)
Healthy Control (HC) Group (n=30):
- Sex matched with BD groups
- No psychiatric history
Exclusion Criteria:
All participants:
- Not between 18-40 years of age
- History of head injury, neurological, pervasive developmental disorder (e.g. autism), systemic medical disease and treatment (medical records, participant report)
- Mini-Mental State Examination score (cognitive state) <24
- Premorbid National Adult Reading Test Intelligent Quotient (NAART IQ) estimate<85
- Visual disturbance: <20/40 Snellen visual acuity
- History of alcohol/substance use disorder (SUD; all substances, including nicotine), and/or illicit substance use (except cannabis) over the last 6 months (SCID-5). Note: lifetime/present cannabis use (at non-abuse (<3 times in the past month) and non SUD levels) will be allowed, given its common usage in BD and young adults. Cannabis SUD over the last 6 months will not be allowed. Urine tests on scan days will exclude current illicit substance use (except cannabis). Salivary alcohol tests on scan days will exclude intoxicated individuals
- MRI exclusion: metallic objects, e.g., surgical implants; claustrophobia; positive pregnancy test for females or self-report pregnancy
- Unable to understand English
- Conditions related to the pancreas, liver, thyroid or gallbladder.
- Taking anticoagulants and/or those with blood dyscrasias (illnesses) who have coagulation disorders (eg, hemophilia) because of the ketomojo finger stick blood tests
- Scoring 3 or higher on positive symptom factor questions on the Positive and Negative Syndrome Scale (PANSS) questionnaire (indicative of psychotic symptoms)
- Currently following a ketogenic diet
- Head circumference larger than 24 inches (62cm) and/or chest circumference larger than 55 inches (139 cm)
- Taken medications for diabetes and weight loss (e.g., Wegovy, Orlistat) in the past month
BD hypomanic group:
- Must be meeting sex proportions: not 50% female
- Must be meeting diagnosis proportions: not 50:50% BDI:II (DSM-5)
- Diagnosis of BD in a manic or euthymic episode
- Score 10 or lower on the Young Mania Rating Scale score(YMRS)
- Using psychotropic medications other than those allowed in inclusion criteria
- Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app
- Does not have a primary care provider (if enrolled in ketogenic diet phase)
BD euthymic group:
- Not meeting sex proportion: not 50% female
- Not meeting diagnosis proportion: not 50:50% BDI:II
- Diagnosis of BD in a depressive, hypomanic, or manic episode
- Score greater than 10 on YMRS
- Using psychotropic medications other than those allowed in inclusion criteria
- Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app
- Does not have a primary care provider (if enrolled in ketogenic diet phase)
Healthy Control (HC) Group
- Not sex-matched with BD groups
- Has psychiatric history
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 1st phase Non-ketogenic Diet / 2nd phase Ketogenic Diet
Participants with Bipolar Disorder will consume a non-ketogenic diet for the first phase of the study and then a ketogenic diet for the second phase of the study |
Consuming a non-ketogenic diet Consuming a ketogenic diet |
|
Experimental: 1st phase Ketogenic Diet / 2nd phase Non-ketogenic Diet
Participants with Bipolar Disorder will consume a ketogenic diet for the first phase of the study and then a non-ketogenic diet for the second phase of the study |
Consuming a non-ketogenic diet Consuming a ketogenic diet |
|
Otro: No diet
Participants without Bipolar Disorder will not participate in the diet phases of the study |
Participants without Bipolar Disorder will not participate in the diet phases of the study |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Blood oxygen level-dependent (BOLD) signal at Scan 1
Periodo de tiempo: Baseline Scan 1 (all participants)
|
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity |
Baseline Scan 1 (all participants)
|
|
Blood oxygen level-dependent (BOLD) signal at Scan 2
Periodo de tiempo: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Blood oxygen level-dependent (BOLD) signal at Scan 3
Periodo de tiempo: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Manic symptoms at Scan 1
Periodo de tiempo: Baseline Scan 1 (all participants)
|
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome) |
Baseline Scan 1 (all participants)
|
|
Manic symptoms at Scan 2
Periodo de tiempo: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome) |
Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Manic symptoms at Scan 3
Periodo de tiempo: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome) |
Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting Glucose at Baseline
Periodo de tiempo: Baseline (all participants)
|
Fasting glucose blood levels |
Baseline (all participants)
|
|
Fasting lipids at Baseline
Periodo de tiempo: Baseline (all participants)
|
Fasting lipid blood levels |
Baseline (all participants)
|
|
Fasting hepatic function panel at Baseline: total protein
Periodo de tiempo: Baseline (all participants)
|
Fasting levels of total protein in the blood |
Baseline (all participants)
|
|
Fasting hepatic function panel at Baseline: albumin
Periodo de tiempo: Baseline (all participants)
|
Fasting levels of albumin in the blood |
Baseline (all participants)
|
|
Fasting hepatic function panel at Baseline: bilirubin
Periodo de tiempo: Baseline (all participants)
|
Fasting levels of bilirubin in the blood |
Baseline (all participants)
|
|
Fasting hepatic function panel at Baseline: liver enzyme
Periodo de tiempo: Baseline (all participants)
|
Fasting levels of liver enzyme in the blood |
Baseline (all participants)
|
|
Fasting Glucose at halfway point through first dietary phase
Periodo de tiempo: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting glucose blood levels |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting lipids at halfway point through first dietary phase
Periodo de tiempo: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting lipid blood levels |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through first dietary phase: total protein
Periodo de tiempo: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of total protein in the blood |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through first dietary phase: albumin
Periodo de tiempo: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of albumin in the blood |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through first dietary phase: bilirubin
Periodo de tiempo: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of bilirubin in the blood |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through first dietary phase: liver enzyme
Periodo de tiempo: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of liver enzyme in the blood |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting Glucose at end of first dietary phase
Periodo de tiempo: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting glucose blood levels |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting lipids at end of first dietary phase
Periodo de tiempo: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting lipid blood levels |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of first dietary phase: total protein
Periodo de tiempo: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of total protein in the blood |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of first dietary phase: albumin
Periodo de tiempo: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of albumin in the blood |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of first dietary phase: bilirubin
Periodo de tiempo: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of bilirubin in the blood |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of first dietary phase: liver enzyme
Periodo de tiempo: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of liver enzyme in the blood |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting Glucose at halfway point through second dietary phase
Periodo de tiempo: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting glucose blood levels |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting lipids at halfway point through second dietary phase
Periodo de tiempo: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting lipid blood levels |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through second dietary phase: total protein
Periodo de tiempo: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of total protein in the blood |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through second dietary phase: albumin
Periodo de tiempo: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of albumin in the blood |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through second dietary phase: bilirubin
Periodo de tiempo: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of bilirubin in the blood |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through second dietary phase: liver enzyme
Periodo de tiempo: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of liver enzyme in the blood |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting Glucose at end of second dietary phase
Periodo de tiempo: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting glucose blood levels |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting lipids at end of second dietary phase
Periodo de tiempo: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting lipids blood levels |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of second dietary phase: total protein
Periodo de tiempo: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of total protein in the blood |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of second dietary phase: albumin
Periodo de tiempo: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of albumin in the blood |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of second dietary phase: bilirubin
Periodo de tiempo: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of bilirubin in the blood |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of second dietary phase: liver enzyme
Periodo de tiempo: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of liver enzyme in the blood |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Gamma-aminobutyric acid (GABA) at Baseline
Periodo de tiempo: Baseline Scan 1 (all participants)
|
Gamma-aminobutyric acid (GABA) concentrations in the brain |
Baseline Scan 1 (all participants)
|
|
Glutamate at Baseline
Periodo de tiempo: Baseline Scan 1 (all participants)
|
Glutamate concentrations in the brain |
Baseline Scan 1 (all participants)
|
|
Lactate at Baseline
Periodo de tiempo: Baseline Scan 1 (all participants)
|
Lactate concentrations in the brain |
Baseline Scan 1 (all participants)
|
|
Gamma-aminobutyric acid (GABA) at end of first dietary phase
Periodo de tiempo: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Gamma-aminobutyric acid (GABA) concentrations in the brain |
Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Glutamate at end of first dietary phase
Periodo de tiempo: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Glutamate concentrations in the brain |
Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Lactate at end of first dietary phase
Periodo de tiempo: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Lactate concentrations in the brain |
Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Gamma-aminobutyric acid (GABA) at end of second dietary phase
Periodo de tiempo: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Gamma-aminobutyric acid (GABA) concentrations in the brain |
Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Glutamate at end of second dietary phase
Periodo de tiempo: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Glutamate concentrations in the brain |
Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Lactate at end of second dietary phase
Periodo de tiempo: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Lactate concentrations in the brain |
Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Average total sleep time during Ketogenic vs Normal diet
Periodo de tiempo: Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals
|
Total sleep time will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home. |
Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals
|
|
Average rest-activity rhythm interdaily stability during Ketogenic vs Normal diet
Periodo de tiempo: Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.
|
Rest-activity rhythm interdaily stability will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home |
Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.
|
|
Ecological momentary assessments (EMA) during the first dietary phase: Mood monitoring
Periodo de tiempo: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood |
The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Ecological momentary assessments (EMA) during the first dietary phase: Energy monitoring
Periodo de tiempo: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy |
The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Ecological momentary assessments (EMA) during the first dietary phase: Suicidality monitoring
Periodo de tiempo: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans |
The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Ecological momentary assessments (EMA) during the second dietary phase: Mood monitoring
Periodo de tiempo: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood |
The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Ecological momentary assessments (EMA) during the second dietary phase: Energy monitoring
Periodo de tiempo: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy |
The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Ecological momentary assessments (EMA) during the second dietary phase: Suicidality monitoring
Periodo de tiempo: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans |
The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Mary Phillips, MD, University of Pittsburgh
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos bipolares y relacionados
- Desordenes mentales
- Trastornos del estado de ánimo
- Trastorno bipolar
- Terapéutica
- Dieta, alimentos y nutrición
- Fenómeno fisiológico
- Fenómenos fisiológicos nutricionales
- Terapia de dieta
- Terapia nutricional
- Dieta
- Dieta, restringido por carbohidratos
- Dieta, cetogénica
Otros números de identificación del estudio
- STUDY23080048
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Informed consent will be collected from study participants that allows for broad sharing of participants' de-identified data. Data transfer procedures will be in accordance with all Institutional Review Board guidelines and federal regulations including HIPAA (Health Insurance Portability and Accountability Act of 1996).
Marco de tiempo para compartir IPD
The principal investigators (PIs) reserve the right to publish on the stated aims in a timely manner. Data will be available for addressing other research questions (i.e. which are not described in funded/pending grants) as soon as the data have been checked for accuracy (a period which will be no later than one year after the completion of each assessment). After the study has ended, the study investigators will continue to test the stated aims, but will also continue to solicit collaborations with outside researchers and to consider data requests in a timely manner.
Criterios de acceso compartido de IPD
Outside investigators must submit a 1)proposal of the study aims, hypotheses, variables/constructs, analytic approach, and estimated duration of the proposed research; 2)resume, qualifications, source of financial support, and conflict of interest statement; 3)sign a data-sharing agreement and confidentiality statement that stipulates using the data for the stated research purposes only, securing the data using appropriate computer technology, not manipulating the data in order to identify participants, acknowledging the grant that supported data collection and management in publications/presentations, and destroying or returning the data after analyses are complete; 4)obtain approval from their Institutional Review Board, and along with other staff members who have access to the data, submit certificates of the University of Pittsburgh Education and Certification Program in Research Practice Fundamentals or provide written documentation of similar human subjects protection training.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .